Jim Jingjun Huang
Jim Jingjun Huang received his Ph.D. in Pharmaceutics from the University of the Sciences in Philadelphia (formerly Philadelphia College of Pharmacy and Sciences) under Joseph B. Schwartz. He has fifteen years of pharmaceutical R&D and management experience in preclinical, clinical, and market formulation development of a variety of oral and parenteral dosage forms through his industrial training and employment with Pfizer (formerly Wyeth), Baxter, AstraZeneca, and Roche. He had lead the formulation efforts in successfully transition of several compounds from discovery to clinical stage of Phase I-II, and commercialization of several speciality injectable products from conception to formulation, manufacturing, technical transfer and finally the market.
Dr. Huang’s research interests are centered on solubility/dissolution rate improvement and controlled delivery of poorly water-soluble drugs through nano/micro-particle and amorphous solid dispersion technology. His publications include studies on drug solubilization and controlled delivery in polymeric solid dispersion systems, amorphous drug delivery systems, controlled release, modeling and simulation, thermal and spectroscopic characterization of amorphous molecular dispersion, drug-polymer interactions and its significance on physical stability of amorphous drug, and micro/nano particulate dosage forms for use in parenteral routs, etc. He credits several publications at peer-reviewed international journals, presentations at international pharmaceutical conference, and patent publications. He has been invited to serve as a reviewer for Journal of Pharmaceutical Sciences, Internation of Pharmaceutics, Journal of Controlled Release, Drug development and Industrial Pharmacy, PDA Journal of Pharmaceutical Science and Technology, Molecular Pharmaceutics, and Pharmaceutical Research. Currently, he is a member of American Association of Pharmaceutical Scientists (AAPS) and American Chemical Society (ACS).